References of "Fardellone, P"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCorrection of vitamin D insufficiency with combined strontium ranelate and vitamin D3 in osteoporotic patients.
Rizzoli, R.; Dawson-Hughes, B.; Kaufman, J.-M. et al

in European Journal of Endocrinology (2014), 170(3), 441-50

OBJECTIVE: This study aims to investigate the efficacy and safety of oral fixed-dose combination of strontium ranelate 2 g/vitamin D3 1000 IU daily vs strontium ranelate 2 g daily for correcting vitamin D ... [more ▼]

OBJECTIVE: This study aims to investigate the efficacy and safety of oral fixed-dose combination of strontium ranelate 2 g/vitamin D3 1000 IU daily vs strontium ranelate 2 g daily for correcting vitamin D insufficiency in osteoporosis. DESIGN: A 6-month international, randomized, double-blind, parallel-group, phase 3 study. METHODS: A total of 518 men and postmenopausal women aged >/=50 years with primary osteoporosis (T-score </=-2.5 s.d.) and serum 25-hydroxyvitamin D (25(OH)D) >22.5 nmol/l were included. Patients were allocated to strontium ranelate 2 g/vitamin D3 1000 IU daily (n=413) or strontium ranelate 2 g daily (n=105). The participants received calcium 1 g daily. The primary endpoint was serum 25(OH)D at last post-baseline evaluation during 3 months. RESULTS: Both groups were comparable at baseline. Mean baseline of 25(OH)D was 44.1+/-14.6 nmol/l. After 3 months, the percentage of patients with 25(OH)D >/=50 nmol/l was higher with strontium ranelate/vitamin D3 vs strontium ranelate (84 vs 44%, P<0.001; adjusted between-group odds ratio=6.7; 95% CI, 4.2-10.9). The efficacy of the fixed-dose combination on 25(OH)D was maintained at 6 months (86 vs 40%, P<0.001). Mean 25(OH)D was 65.1 and 49.5 nmol/l, respectively, after 3 months and 66.9 and 45.4 nmol/l after 6 months. Physical performance improved in both groups. Falls were 17 and 20% in the strontium ranelate/vitamin D3 and strontium ranelate groups respectively. Parathyroid hormone levels were inversely correlated with 25(OH)D. No clinically relevant differences in safety were observed. CONCLUSIONS: This study confirms the efficacy and safety of fixed-dose combination of strontium ranelate 2 g/vitamin D3 1000 IU for correction of vitamin D insufficiency in osteoporotic patients. [less ▲]

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailEfficacy of a strontium ranelate 2 G/vitamin D3 1000 UI combination on the correction of vitamin D insufficiency
Rizzoli, R; Dawson-Hughes, B; Kaufman, JM et al

in Osteoporosis International (2012, May), 23(S2), 225

Detailed reference viewed: 47 (5 ULg)
Full Text
Peer Reviewed
See detailCorrection of vitamin D insufficiency with the fixed daily combination strontium ranelate 2 g/vitamin D3 1000 IU over 12 months
Rizzoli, R; Dawson-Hughes, B; Kaufman, JM et al

in Arthritis and Rheumatism (2012), 64(S10), 835

Detailed reference viewed: 18 (3 ULg)
Full Text
Peer Reviewed
See detailVitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice.
Souberbielle, J. C.; Body, J. J.; Lappe, J. M. et al

in Autoimmunity Reviews (2010), 9(11), 709-15

BACKGROUND: There is increasing evidence that, in addition to the well-known effects on musculoskeletal health, vitamin D status may be related to a number of non-skeletal diseases. An international ... [more ▼]

BACKGROUND: There is increasing evidence that, in addition to the well-known effects on musculoskeletal health, vitamin D status may be related to a number of non-skeletal diseases. An international expert panel formulated recommendations on vitamin D for clinical practice, taking into consideration the best evidence available based on published literature today. In addition, where data were limited to smaller clinical trials or epidemiologic studies, the panel made expert-opinion based recommendations. METHODS: Twenty-five experts from various disciplines (classical clinical applications, cardiology, autoimmunity, and cancer) established draft recommendations during a 2-day meeting. Thereafter, representatives of all disciplines refined the recommendations and related texts, subsequently reviewed by all panelists. For all recommendations, panelists expressed the extent of agreement using a 5-point scale. RESULTS AND CONCLUSION: Recommendations were restricted to clinical practice and concern adult patients with or at risk for fractures, falls, cardiovascular or autoimmune diseases, and cancer. The panel reached substantial agreement about the need for vitamin D supplementation in specific groups of patients in these clinical areas and the need for assessing their 25-hydroxyvitamin D (25(OH)D) serum levels for optimal clinical care. A target range of at least 30 to 40 ng/mL was recommended. As response to treatment varies by environmental factors and starting levels of 25(OH)D, testing may be warranted after at least 3 months of supplementation. An assay measuring both 25(OH)D(2) and 25(OH)D(3) is recommended. Dark-skinned or veiled individuals not exposed much to the sun, elderly and institutionalized individuals may be supplemented (800 IU/day) without baseline testing. [less ▲]

Detailed reference viewed: 48 (4 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate : long-term efficacy over 8 years in postmenopausal osteoporotic women
Reginster, Jean-Yves ULg; Sawicki, A; Roces-Varela, A et al

in Arthritis and Rheumatism (2008, October), 58

Detailed reference viewed: 15 (5 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate: 8 years efficacy on vertebral and nonvertebral fractures in postmenopausal osteoporotic women
Reginster, Jean-Yves ULg; Sawicki, A.; Roces-Varela, A. et al

in Osteoporosis International (2008, April), 19(Suppl.1), 131-132

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailLe ranélate de strontium maintient son efficacité sur 8 ans chez les femmes ménopausées ostéoporotiques
Reginster, Jean-Yves ULg; Sawicki, A.; Races-Varela, A. et al

in Revue du Rhumatisme (2008), 75

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailRelationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate
Bruyère, Olivier ULg; Roux, C.; Detilleux, Johann ULg et al

in Journal of Clinical Endocrinology and Metabolism (2007), 92(8), 3076-3081

Objective: Our objective was to analyze the relationship between bone mineral density (BMD) changes and fracture incidence during 3-yr treatment with strontium ranelate. Patients: Women from the strontium ... [more ▼]

Objective: Our objective was to analyze the relationship between bone mineral density (BMD) changes and fracture incidence during 3-yr treatment with strontium ranelate. Patients: Women from the strontium ranelate arm of the Spinal Osteoporosis Therapeutic Intervention study and the TReatment Of Peripheral OSteoporosis study were evaluated. Outcome Measures: The outcome measures included BMD at the lumbar spine, femoral neck, and total proximal femur assessed at baseline and after a follow-up of 1 and 3 yr; semiquantitative visual assessment of vertebral fractures; and nonvertebral fractures based on written documentation. Results: After 3 yr of strontium ranelate treatment, each percentage point increase in femoral neck and total proximal femur BMD was associated with a 3%(95% adjusted confidence interval, 1-5%) and2% (1-4%) reduction in risk of a new vertebral fracture, respectively. The 3- yr changes in femoral neck and total proximal femur BMD explained 76% and 74%, respectively, of the reduction in vertebral fractures observed during the treatment. Three-year changes in spine BMD were not statistically associated with the incidence of new vertebral fracture (P = 0.10). No significant associations were found between 3- yr changes in BMD and incidence of new nonvertebral fractures, but a trend was found for femoral neck BMD (P = 0.09) and for total proximal femur BMD (P = 0.07). An increase in femoral neck BMD after 1 yr was significantly associated with the reduction in incidence of new vertebral fractures observed after 3 yr (P = 0.04). Conclusion: During 3-yr strontium ranelate treatment, an increase in femoral neck BMD was associated with a proportional reduction in vertebral fracture incidence. [less ▲]

Detailed reference viewed: 48 (21 ULg)
Full Text
Peer Reviewed
See detailEffect of age on a fractal bone texture parameter assessed by high resolution digital X Ray: a multicenter pilot study
Gadois, C.; Zegels, Brigitte; Dohuu, J. P. et al

in Osteoporosis International (2007, March), 18(Suppl.1), 102

Detailed reference viewed: 14 (2 ULg)
Full Text
Peer Reviewed
See detailVertebral fracture risk reduction with strontium ranelate in women with post-menopausal osteoporosis is independent of baseline risk factors
Roux, Christian; Reginster, Jean-Yves ULg; Fechtenbaum, Jacques et al

in Osteoporosis International (2006, June), 17(Suppl.2), 92

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailVertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors
Roux, C.; Reginster, Jean-Yves ULg; Fechtenbaum, J. et al

in Journal of Bone and Mineral Research (2006), 21(4), 536-542

Strontium ranelate (2 g/day) was studied in 5082 postmenopausal women. A reduction in incident vertebral fracture risk by 40% was shown after 3 years. This effect was independent of age, initial BMD, and ... [more ▼]

Strontium ranelate (2 g/day) was studied in 5082 postmenopausal women. A reduction in incident vertebral fracture risk by 40% was shown after 3 years. This effect was independent of age, initial BMD, and prevalent vertebral fractures. Introduction: Strontium ranelate is an orally active treatment able to decrease the risk of vertebral and hip fractures in osteoporotic postmenopausal women. The aim of this study was to assess the efficacy of strontium ranelate according to the main determinants of vertebral fracture risk: age, baseline BMD, prevalent fractures, family history of osteoporosis, baseline BMI, and addiction to smoking. Materials and Methods: We pooled data of two large multinational randomized double-blind studies with a population of 5082 (2536 receiving strontium ranelate 2 g/day and 2546 receiving a placebo), 74 years of age on average, and a 3-year follow-up. An intention-to-treat principle was used, as well as a Cox model for comparison and relative risks. Results: The treatment decreased the risk of both vertebral (relative risk [RR] = 0.60 [0.53-0.69] p < 0.001) and nonvertebral (RR = 0.85 [0.74-0.99] p = 0.03) fractures. The decrease in risk of vertebral fractures was 37% (p = 0.003) in women <70 years, 42% (p < 0.001.) for those 70-80 years of age, and 32% (P = 0.013) for those >= 80 years. The RR of vertebral fracture was 0.28 (0.07-0.99) in osteopenic and 0.61. (0.53-0.70) in osteoporotic women, and baseline BMD was not a determinant of efficacy. The incidence of vertebral fractures in the placebo group increased with the number of prevalent vertebral fractures, but this was not a determinant of the effect of strontium ranelate. In 2605 patients, the risk of experiencing a first vertebral fracture was reduced by 48% (p < 0.001.). The risk of experiencing a second vertebral fracture was reduced by 45% (p < 0.001,; 1100 patients). Moreover, the risk of experiencing more than two vertebral fractures was reduced by 33% (p < 0.001; 1365 patients). Family history of osteoporosis, baseline BMI, and addiction to smoking were not determinants of efficacy. Conclusions: This study shows that a 3-year treatment with strontium ranelate leads to antivertebral fracture efficacy in postmenopausal women independently of baseline osteoporotic risk factors. [less ▲]

Detailed reference viewed: 25 (3 ULg)
Full Text
Peer Reviewed
See detailVertebral fracture risk reduction with strontium ranelate in women with post-menopausal osteoporosis is independent of baseline risk factors
Roux, Christian; Reginster, Jean-Yves ULg; Fechtenbaum, Jacques et al

in Osteoporosis International (2006, March), 17(Suppl.1), 50

Detailed reference viewed: 2 (0 ULg)
Full Text
Peer Reviewed
See detailOne-year increase in hip (hip or femoral neck) bone mineral density pridicts long-term (3 years) decrease in vertebral fracture incidence in patients treated with strontium ranelate
Bruyère, Olivier ULg; Fardellone, P.; Kaufman, Jean-Marc et al

in Osteoporosis International (2006, March), 17(Suppl.1), 96

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women whatever the baseline vertebral fractures status
Roux, Christian; Fardellone, P.; Fechtenbaum, Jacques et al

in Annals of the Rheumatic Diseases (2005, June), 64(Suppl.III), 359

Detailed reference viewed: 10 (6 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral fractures in osteoporotic postmenopausal women whatever the baseline vertebral fracture status
Fardellone, P.; Roux, C.; Fechtenbaum, J. et al

in BONE (2005), 36(S2), 403

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral and non-vertebral fractures in Caucasian women with postmenopausal osteoporosis
Adami, Silvio; Meunier, Pierre J; Devogelaer, Jean-Pierre et al

in Osteoporosis International (2004, May), 15(Suppl.1), 93-94

Detailed reference viewed: 8 (3 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of vertebral and non-vertebral fractures in Caucasian women with post-menopausal osteoporosis.
Adami, S; Meunier, J; Devogelaer, JP et al

in Calcified Tissue International (2004), 74(S1), 37-38

Detailed reference viewed: 16 (4 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Sawicki, A.; Devogelaer, Jean-Pierre et al

in Osteoporosis International (2002, November), 13(Suppl.3), 14

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate réduit le risque de fracture vertébrale chez des patientes traitées 3 ans pour ostéoporose postménopausique
Meunier, P. J.; Roux, C.; Fardellone, P. et al

in Revue du Rhumatisme (2002), 69

Detailed reference viewed: 7 (2 ULg)